-
殷拓大中华基金出售老百姓股份
殷拓大中华基金以每股55元人民币出售所持老百姓大药房剩余的24.78%股份。出售价格较IPO定价人民币16.4元溢价235.2%。老百姓大药房是中国领先的连锁药店龙头。 老百姓大药房透过善用殷拓的网络以及在医疗健康和零售行业的丰富经验快速增长 老百姓大药房在2015年于上海证券交易所上市,是中国第一家有外国私募股权基金作为共同控股股东的上市公司 殷拓大中华基金(“殷拓”)已将所持老百姓大药房连锁股份有限公司(“老百姓大药房”或“公司”,股票代码:603883)剩余的24.78%股份出售给春华资本和方源资本(“财团”)。老百姓大药房是中国领先的A股上市零售连锁药店。...
-
EQT sells remaining stake in LBX Pharmacy
EQT Greater China sells remaining 24.78 percent in LBX Pharmacy, a leading discount pharmacy superstore chain in China, at RMB 55.0 per share, 235.2 percent above the IPO price of RMB 16.4 LBX Pharmacy has experienced strong growth and transformation during EQT’s ownership, leveraging the EQT...
-
Initial Public Offering of LBX Pharmacy on Shanghai Stock Exchange
LBX Pharmacy (“LBX” or the “Group”), a portfolio company of the EQT Greater China II Limited (“EQT Greater China”), has successfully completed its Initial Public Offering on the Shanghai Stock Exchange on April 23, 2015. The offer was oversubscribed 233 times with RMB 256.5 billion in demand...
-
EQT acquires retail pharmacy chain LBX Pharmaceuticals in China
EQT Greater China II ("EQT") hereby announces the acquisition of a co-control stake of the retail pharmacy chain Hunan LaoBaiXing Pharmaceuticals Company Limited (“LBX”). LBX is a discount pharmacy super-store chain targeting at customers with chronic diseases. After the acquisition, EQT owns 48%...
Filters applied: #LBX Pharmacy